Alglucerase

An enzyme replacement therapy derived from human placental tissue used to treat Gaucher disease, a rare genetic disorder in which a deficiency of glucocerebrosidase allows fatty substances to accumulate in organs. Regular infusions supply the missing enzyme, reducing organ enlargement and improving blood counts and bone complications.

Provides exogenous replacement of the deficient enzyme, restoring the metabolic pathway and clearing accumulated substrates from affected tissues.

Yes, Alglucerase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.